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Abstract
The aggregation of the microtubule-associated protein tau is a seminal event in many 
neurodegenerative diseases, including Alzheimer’s disease. The inhibition or reversal of tau 
aggregation is therefore a potential therapeutic strategy for these diseases. Fungal natural products 
have proven to be a rich source of useful compounds having wide varieties of biological activities. 
We have previously screened Aspergillus nidulans secondary metabolites for their ability to inhibit 
tau aggregation in vitro using an arachidonic acid polymerization protocol. One aggregation 
inhibitor identified was asperbenzaldehyde, an intermediate in azaphilone biosynthesis. We 
therefore tested 11 azaphilone derivatives to determine their tau assembly inhibition properties in 
vitro. All compounds tested inhibited tau filament assembly to some extent, while four of the 11 
compounds had the advantageous property of disassembling preformed tau aggregates in a dose-
dependent fashion. The addition of these compounds to the tau aggregates reduced both the total 
length and numbers of tau polymers. The most potent compounds were tested in in vitro reactions 
to determine whether they interfere with tau’s normal function of stabilizing microtubules (MTs). 
We found that they did not completely inhibit MT assembly in the presence of tau. These 
derivatives are very promising lead compounds for tau aggregation inhibitors and, more excitingly, 
for compounds that can disassemble pre-existing tau filaments. They also represent a new class of 
anti-tau aggregation compounds with a novel structural scaffold.
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Introduction
Alzheimer’s disease (AD) is the most common form of dementia. This devastating condition 
is made worse by the relative lack of therapies available for its treatment. Current 
therapeutics largely target cholinergic pathways and do little to slow or reverse the 
accumulation of aggregates of either beta amyloid or the microtubule-associated protein tau 
into senile plaques or neurofibrillary tangles respectively. The location and amount of tau 
aggregation into neurofibrillary tangles directly correlates with the type and severity of the 
disease progression1. Therefore, there is great interest in identifying small molecules that 
may inhibit or reverse tau aggregation. Recently a tau aggregation inhibitor, a stable, 
reduced form of methylthioninium chloride, has reached phase 3 clinical trials2, validating 
the potential of tau aggregation as a target, but there is certainly a need for additional lead 
anti-tau aggregation compounds for further development into therapeutics.
An ideal tau aggregation inhibitor should inhibit the assembly of tau aggregates and 
disassemble pre-formed tau aggregates as well. Inhibitors of tau aggregation also should not 
impair the normal function of tau to bind and stabilize microtubules. Previously identified 
tau aggregation inhibitors, including molecules belonging to the anthraquinone class, have 
had widely diverse structures, with fused ring structures being a commonly occurring 
structural motif3. Recent emphasis has been placed on identifying natural products with 
novel scaffolds that may have useful properties for the treatment of AD by inhibiting tau 
aggregation4, 5.
Fungi have historically been a good source of secondary metabolites, which have useful 
pharmacological properties such as antibiotics, immunosuppressants, and cholesterol-
lowering drugs, among others6. We have identified numerous biosynthetic pathways in 
Aspergillus nidulans that lead to production of a wide range of secondary metabolites6–9. In 
a previous study, we tested several A. nidulans secondary metabolites for their ability to 
inhibit tau aggregation in vitro and found that several were active inhibitors at micromolar 
concentrations, although they did not have tau disaggregation properties10. Among these, 
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two, ω-dihydroxyemodin and asperthecin, belonged to the anthraquinone class of 
compounds, a class that includes compounds shown to inhibit tau aggregation. A third 
compound, asperbenzaldehyde, however, was structurally distinct from previously identified 
tau aggregation inhibitors. Asperbenzaldehyde is also interesting in that it is an intermediate 
in the biological synthesis of azaphilone compounds11.
Azaphilones are known to exhibit a great variety of biologically important activities 
including inhibitions of gp120–CD4 binding12 and heat shock protein 90 (Hsp90)13–15, 
among others. Several azaphilones have been shown to have lipoxygenase inhibitor 
activity11. Inhibition of lipoxygenases may help reduce fatty acid metabolite levels that are 
elevated in AD16. Azaphilones, including lipoxygenase-inhibiting azaphilones, can be 
obtained from asperbenzaldehyde using a 2–3 step semisynthetic route11. We therefore 
sought to determine whether azaphilones derived from asperbenzaldehyde inhibit tau 
aggregation, hoping that they might be a useful step in finding compounds with two 
biological targets relevant to treating AD.
Beginning with asperbenzaldehyde, which was purified from a fungal strain engineered to 
overproduce this compound, the azaphilones were prepared as previously described using 
two schemes11. The first employs p-toluenesulfonic acid to form the 2-benzopyrilium salt 
followed by oxidation by lead tetraacetate with or without halogenation. The second scheme 
employs the hypervalent-iodine-mediated phenol oxidative dearomatization of the 2-
benzopyrilium salt with o-iodoxy-benzoic acid followed by halogenation and/or a Wittig 
olefination with carbethoxymethylenetriphenylphosphorane.
Using standard biochemical assays, we investigated the ability of these compounds to alter 
the aggregation of tau and its stabilization of microtubules. We found that while all 
compounds inhibited tau aggregation, a smaller subset had the added activity of 
disassembling pre-formed tau aggregates. The compounds most effective at inhibiting tau 
aggregation and disassembling pre-formed tau filaments also allowed tau to retain the 
majority of its microtubule stabilizing functions.
Results
Eleven compounds with the same azaphilone backbone differing at three points of diversity 
(R1, R2, and R3) were used in this study (Figure 1). Tau polymerization was initiated in vitro 
using a standard arachidonic acid induction assay17. To determine whether the compounds 
could inhibit assembly of tau filaments, each of the compounds, at a final concentration of 
200 µM, was preincubated with 2 µM tau for 20 min before the addition of 75 µM 
arachidonic acid. The degree of tau aggregation inhibition for each compound was 
determined using a membrane filter assay18. This assay has been used previously to screen 
A. nidulans secondary metabolites including anthraquinones, xanthones, polyketides, a 
benzophenone and the asperbenzaldehyde compound that was the parent compound for the 
synthesis of the azaphilones used in this study10. A mixture of antibodies to the amino 
terminal region, central region and carboxy terminal region of tau (tau 12, tau 5, and tau 7 
respectively) was used to detect tau aggregates. In this assay, only compound aza-11 
significantly reduced the amount of tau aggregation detected (Figure 2A). Compounds 
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aza-13 and aza-15 significantly increased the amount of tau aggregation and the remaining 
compounds had no significant effect (Figure 2A). However, when antibodies against toxic 
species of tau were employed for detection, very different results were observed. All aza 
compounds completely abolished recognition by the TOC1 antibody, which recognizes toxic 
oligomers in vitro and in Alzheimer’s disease tissue19, as compared to controls without 
compound (Figure 2B). Similarly, significant reductions in recognition by TNT1, an 
antibody that recognizes the phosphatase-activating domain of tau and is exposed in 
pathological forms of tau20, were observed for all aza compounds as compared to controls 
without compound (Figure 2C).
When the resulting tau aggregates from the inhibition reactions were visualized by electron 
microscopy, there were abundant numbers of long filaments in the absence of added 
compound (Figure 3). Surprisingly, all the azaphilones inhibited the formation of long tau 
filaments that were observed in the absence of compounds. Instead, amorphous small 
aggregates were observed after treatment with the compounds (Figure 3). This degree of tau 
aggregation inhibition was similar to what was observed by electron microscopy for 
asperbenzaldehyde and asperthecin, and stronger than what was observed for 2,ω-
dihydroxyemodin in a prior study10. Because tau aggregation inhibitors that inhibit filament 
formation have previously been shown to stabilize off-pathway soluble oligomers that are 
large enough to be trapped in the membrane filter assay21, we believe that the mixture of tau 
antibodies to normal tau was detecting these aggregates in the filter trap assay (Figure 2A). 
These aggregates do not seem to be toxic because of their lack of reactivity to TOC1 (Figure 
2B) and TNT1 (Figure 2C).
To determine whether these compounds can disassemble pre-formed tau aggregates, tau 
aggregation was allowed to proceed for six hours before the addition of compounds to a final 
concentration of 200 µM. After 12 hours the effect of compounds on the tau aggregation 
were examined by filter trap assay using the mixture of antibodies against normal tau 
(Figure 4). All compounds reduced the amount of preformed tau filaments, with compounds 
aza-8, aza-9, aza-11, aza-12, and aza-13 having the greatest activity. Electron microscopy 
was used to validate and extend the results from the filter trap assay. Compounds aza-8, 
aza-9, aza-12 and aza-13 substantially reduced the preexisting filament mass while the other 
compounds had less effect (Figure 5). To test whether compounds aza-8, aza-9, aza-12, and 
aza-13 were not simply blocking the adherence of tau filaments to the electron microscopy 
grids, compounds were added to pre-formed tau filaments and were immediately prepared 
for electron microscopy without allowing time for disassembly to occur. Under these 
conditions, none of the compounds blocked the binding of the filaments to the grid 
(Supplemental Figure S2). Quantitative analysis of the filament lengths in the presence and 
absence of compounds confirmed that compounds aza-8, aza-9, aza-12 and aza-13 had fewer 
aggregates overall compared to reactions without compound and virtually no filaments 
remaining greater than 200 nm in length (Figure 6).
The IC50 of the four most potent compounds was determined using the filter trap assay. The 
amount of pre-formed filaments remaining following treatment with compounds for 12 
hours was reduced in a concentration dependent manner for all four compounds tested 
(Figure 7). Compound aza-9 had an IC50 of 56 ± 14 µM, compared to 118 ± 19 µM, 98 ± 16 
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µM and 216 ± 18 µM for compounds aza-8, aza-12 and aza-13 respectively, indicating that 
aza-9 has the most activity for dissolving pre-formed tau filaments in vitro (Figure 7).
In a number of studies heparin has been used to induce tau aggregation. Because heparin-
induced tau filaments might be different from arachidonic acid induced filaments, we wished 
to determine if aza 9 inhibited heparin-induced tau aggregation or disassembled heparin 
assembled tau aggregates. We chose aza 9 because it was the most potent compound among 
the 11 azaphilones. Filter trap assays were performed using the mixture of antibodies against 
normal tau, the TOC1 antibody and the TNT1 antibody. Aza 9 significantly reduced the 
assembly of TOC1 and TNT1 positive aggregates (Figure 8A). The addition of aza 9 also 
resulted in the significant disassembly of pre-formed filaments recognized by the TOC1 and 
TNT1 antibodies (Figure 8B).
We chose the most potent azaphilone derivatives aza-8, aza-9, aza-12 and aza-13 to 
determine their effects on the normal function of tau to stabilize microtubules. Tubulin was 
mixed with tau in the presence or absence of 90 µM compound and the resulting microtubule 
formation was monitored by turbidity. All polymerization curves were fit using a Gompertz 
growth equation (Figure 9). While all four compounds affected the apparent rate and 
maximum amount of microtubule formation at the concentration tested (Table 1), tau still 
retained a significant ability to stabilize microtubule formation.
Discussion
Tau based therapeutic strategies have recently been gaining additional attention largely due 
to the major role tau pathology plays in many neurological disorders including Alzheimer’s 
disease. Several tau-directed therapeutic strategies with disease-modifying potential have 
been identified including modulating tau phosphorylation, microtubule stabilization, tau 
aggregation inhibitors and tau clearance using antibodies22–30. Conversion of soluble 
monomeric tau into insoluble tau aggregates could, potentially, result in both loss of function 
and gain of function toxicities31. Therefore, inhibiting aggregation of tau might prevent 
formation of the toxic oligomers or tangles. Inhibiting aggregation could also increase the 
levels of monomeric tau, thereby increasing the chances for its clearance through chaperone 
mediated processes32. Previous studies have identified several tau aggregation inhibitor 
(TAI) molecules including those belonging to the class of anthraquinones, phenothiazines, 
and a benzothiazolidine derivatives among others3, 33, 34. One TAI, a stable, reduced form of 
methylthioninium chloride, is currently in Phase III clinical trials2, indicating this approach 
has promise and it is, consequently, worthwhile to identify additional structural backbones 
with this activity. Many of the previously identified TAIs are comprised of fused ring 
structures believed to be capable of interacting with the β-sheet structures formed in tau 
aggregates, thereby inhibiting formation of tau filaments10, 21.
Fungal extracts are known to include pharmaceutically important secondary metabolites35. 
We therefore previously screened 17 secondary metabolites obtained from the fungus 
Aspergillus nidulans for TAIs due to their structural similarity to previously identified 
TAIs10. From this screen we identified 3 compounds that inhibited tau aggregation at 
micromolar concentrations. Two of these compounds belonged to the anthraquinone class of 
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compounds and one was structurally unique from all the previously identified TAIs. We 
were particularly interested in this compound – asperbenzaldehyde. Asperbenzaldehyde is a 
precursor to an important class of natural products called azaphilones. Azaphilones are a 
structurally diverse group of polyketides that share a highly oxygenated bicyclic core and 
chiral quaternary center36. The azaphilones used in this study were obtained by semi-
synthetic diversification of asperbenzaldehyde.
All eleven azaphilones inhibited the formation of tau filaments but some of them produced 
small amorphous tau aggregates, which can be seen in the electron micrographs in Figure 3. 
These aggregates were not recognized by TOC119 and TNT120 antibodies, which bind to 
toxic forms of tau, therefore we believe these compounds promote the formation of small 
off-pathway aggregates of tau which are not toxic and do not act as seeds for further tau 
filament assembly. The induction of these aggregates could be similar to soluble aggregates 
of tau induced by porphyrin pthalocyanine tetrasulfonate that have a different conformation 
from insoluble toxic tau oligomers21.
From a therapeutic point of view, TAIs would be more useful if they could also dissolve pre-
formed tau filaments because they could theoretically be beneficial to patients that already 
demonstrate cognitive impairments. We found that a subset of the compounds, aza-8, aza-9, 
aza-12, and aza-13, showed this property. These four compounds have Br or Cl at position 
R1, while the other compounds have either I or H at R1 (Figure 1). Therefore, halogenation 
at position R1 may be not necessarily important for inhibition of tau filament formation, but 
electron-withdrawing groups at R1 specifically seem to enhance disassembly of tau 
filaments. Cl and Br are more electronegative (3.0 and 2.8 respectively), than I (2.5) and H 
(2.1) indicating that increased electronegativity at position R1 could have a significant 
impact on the activity of tau aggregation inhibitors with this scaffold. The four disassembly 
causing compounds have a ketone at position R3, while presence of the CHCO2Et moiety at 
the same position seems to virtually eliminate disassembly, even with halogenation. The 
impact of the chemical groups at the R2 position seems to be dependent upon the 
substitution at R1. Compounds aza-8 and aza-12 both have Cl at R1, but possess acetate and 
hydroxyl groups at R2, respectively. Despite this structural difference, there is no significant 
difference in their activity levels. However compounds aza-9 and aza-13 both containing Br 
at R1, and acetate and hydroxyl groups at R2, respectively differ in their levels of activity. 
Aza-9 is more potent than aza-13, therefore positioning of the acetate group at R2 in the 
presence of a Br at R1 might be important for compound activity.
Additionally, all four disassembly causing compounds have lipoxygenase-1 inhibitory 
activity in the low micromolar range (IC50 of 2–8µm)11. Inhibition of LOX-1 may help 
reduce fatty acid metabolites of arachidonic acid and docasahexanoic acid that are elevated 
in Alzheimer’s disease16. These compounds could therefore have two positive therapeutic 
activities in tau dementias. The relatively high IC50 values of our compounds indicate that 
they are unlikely to be of therapeutic value and we do not know if they have suitable 
bioavailability or pharmacokinetic properties. It is important, however, to identify new 
scaffolds with the appropriate biological activity for further development. We believe these 
compounds provide a novel TAI scaffold with the added features that they inhibit LOX-1 
and some of them disassemble pre-formed tau aggregates.
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In conclusion, this study shows that these compounds inhibit assembly of tau aggregates, 
disassemble preformed tau aggregates, and partially preserve tau’s ability to bind to tubulin 
and promote microtubule assembly. These compounds provide a promising novel scaffold 
for TAI molecules. The structure-activity relationship studies give us several leads for the 
probable important chemical groups required in this scaffold structure required for the anti-
tau aggregation activity of the compounds. Further studies on the interaction between the 




Full length 2N4R tau (441 amino acids) was expressed in E. coli and purified as described 
previously37. Arachidonic acid (ARA) was purchased from Cayman Chemicals (Ann Arbor, 
MI). Heparin sodium salt was purchased from SIGMA (St. Louis, MO). Asperbenzaldehyde 
was purified from Aspergillus nidulans and converted to the compounds aza-7 through 
aza-17 (Figure 1) as described previously11 with the following minor modifications. We 
constructed a number of strains with various promoter combinations and used a variety of 
induction conditions to maximize asperbenzaldehyde production. Our best yields were 
obtained with strain LO8355 (pyrG89, pyroA4, riboB2, nkuA::argB, stcJ::AfriboB, 
AN1029(p):: AfpyrG-alcA(p), AN1033::AfpyroA, alcR(p)::ptrA-gpdA(p)). In this strain, the 
promoter of asperfuranone biosynthesis transcription factor AN1029 (using the AspGD 
nomenclature (http://aspergillusgenomes.org/)) is replaced with the highly inducible alcA 
promoter and the alcR promoter is replaced with the strong, constitutive gpdA promoter 
(−1241 to −1). AN1033 is replaced with the AfpyroA gene to interrupt the asperfuranone 
biosynthesis pathway causing asperbenzaldehyde to accumulate. Growth was in lactose 
minimal medium (20 g/L lactose, 6 g/L NaNO3, 0.52 g/L KCl, O.52 g/L MgSO4,·7H2O, 
1.52 g/L KH2PO4, 1 mL/L trace elements solution)38. Spores were inoculated at 106/mL 
into 500 mL of medium in a 2L flask. Incubation was at 37 °C on a gyratory shaker and 
induction was with 30 mM methyl-ethyl-ketone, added 55 hours after inoculation. Cultures 
were harvested six days after inoculation. Yields of purified asperbenzaldehyde were greater 
than 2 g/L representing an approximate conversion of 10% of the carbon source to final 
product. Additional information on the purity of the compounds can be found in 
supplemental materials.
Inhibition of tau aggregation
75 µM arachidonic acid was used to initiate the aggregation of 2 µM tau in polymerization 
buffer (PB, 10 mM HEPES (pH 7.64), 5 mM DTT, 100 mM NaCl, 0.1 mM EDTA, and 
3.75% ethanol) in vitro as previously described17. Compounds dissolved in DMSO were 
added to a final concentration of 200 µM and incubated with tau protein in PB 20 minutes 
prior to the addition of arachidonic acid. The reactions were allowed to proceed for 16 h at 
room temperature before analysis10. For heparin induced tau assembly inhibition reactions, 
0.6 µM heparin was used to initiate aggregation on 2 µM tau in polymerization buffer (PB, 
10mM HEPES (pH 7.64), 5 mM DTT, 17.7 mM NaCl) in vitro. Compounds dissolved in 
DMSO were added to a final concentration of 200 µM and incubated with tau protein in PB 
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20 minutes prior to the addition of heparin. The reactions were allowed to proceed for 16 h 
at 37 °C before analysis.
Disassembly of pre-formed filaments
Pre-formed tau filaments were generated with 2 µM tau and 75 µM ARA in PB as described 
above for 6 h at room temperature. Compounds dissolved in DMSO were added to the tau 
solution at final concentrations indicated in the Results section and figure legends. The 
reactions were allowed to proceed at room temperature for 12 h before analysis. For heparin 
induced tau aggregation assays, pre- formed tau filaments were generated with 2 µM tau and 
0.6 µM heparin in PB as described above for 12 h at 37 °C. Compounds dissolved in DMSO 
were added to the tau solution at final concentrations indicated in the Results section and 
figure legends. The reactions were allowed to proceed at 37 °C for 24 h before analysis.
Filter trap assay
The amount of tau aggregates following assembly or disassembly reactions was determined 
by filter trap assay as described previously10. Reactions were diluted into TBS such that they 
contained 20 ng protein in 300 µL. For heparin induced tau aggregation reactions, the 
reactions were diluted into TBS such that they contained 60 ng protein in 300 µL. Solutions 
were passed through a nitrocellulose membrane using house vacuum in a dot-blot apparatus. 
The aggregates trapped on the membrane were detected by either general antibodies (a 
mixture of Tau 539 at 1:50,000 dilution, Tau 1240 at 1:250,000 dilution and Tau 741 at 
1:250,000 dilution), or antibodies to toxic conformations (TNT119 at 1:200,000 or TOC120 
at 1:7,000). All antibodies were a kind gift from Drs. Nick Kanaan and Lester I. Binder. 
HRP-linked Goat anti-mouse IgG (general antibodies and TNT1) or HRP-linked Goat anti-
mouse IgM (TOC1) (Thermo Scientific, Rockford, IL) were used as the secondary 
antibodies and blots were developed using ECL (enhanced chemiluminescence) Western 
Blotting Analysis System (GE Healthcare, Buckinghamshire, UK). Images were captured 
with a Kodak Image Station 4000R or ChemiDoc-It2 Imager and were quantified using the 
histogram function of Adobe Photoshop 7.0. Statistical analyses were performed using 
unpaired t-tests to compare the triplicate values to control values.
Transmission electron microscopy
Polymerization reaction samples were diluted 1:10 in PB and fixed with 2% glutaraldehyde 
for 5 min. Fixed samples were placed on formvar carbon-coated grids and stained with 
uranyl acetate as previously described10. Images were captured with a Technai F20 XT Field 
emission transmission electron microscope (FEI Co., Hillsboro, OR) and Gatan Digital 
Micrograph imaging system (Gatan, Inc., Pleasanton, CA). The filaments were quantified 
using Image-Pro Plus 6.0 software (Media Cybernetics, Inc., Rockville, MD) as previously 
described10. For quantitative analysis, filament lengths were placed into bins as described in 
results. Statistical analyses were performed using unpaired t-tests to compare 4 or 5 
replicates for each bin size with the no compound data serving as reference values.
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Polymerization of tubulin was measured using a Tubulin Polymerization Assay kit BK006P 
(Cytoskeleton, Inc., Denver, CO) following the manufacturer’s protocol. Briefly, 2 mg/ml 
porcine tubulin was incubated with 1.5 µM tau and 90 µM aza-8, aza-9, aza-12 or aza-13 
compounds. Tubulin polymerization was monitored by turbidity at 340 nm in a Varian 50 
MPR microplate reader at 37 °C for 1 h. Experiments were performed in triplicate, averaged 
and fit to a Gompertz growth equation as previously described42 using the equation:
Where y is the amount of microtubule polymerization measured at time t, a is the maximum 
amount of microtubule polymerization observed at an absorbance of 340 nm (Max), ti is the 
point of inflection of the curve at the time of maximum growth rate in minutes, and b is 
inversely proportional to the apparent rate of polymerization (kapp, min−1). The average 
values for the parameters a, b and ti were determined and compared to the no-compound 
control using a paired t-test to determine statistical significance *p≤ 0.05; **p≤ 0.01; ***p≤ 
0.001.
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Figure 1. Compounds used in this study
The core structure of the azaphilone compounds is shown with the positions of modications 
indicated by R1, R2 and R3. A.-K.: The structures of the 11 compounds used in this study: 
A) aza-7, B) aza-8, C) aza-9, D) aza-10, E) aza-11, F) aza-12, G) aza-13, H) aza-14, I) 
aza-15, J) aza-16, and K) aza-17.
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Figure 2. Filter trap assay of tau filament formation
Tau polymerization reactions in A), B), and C) were performed with 2 µM tau and 75 µM 
arachidonic acid either with or without 200 µM compound. The compounds used are listed 
on the X- axis. The resulting amount of tau filament formation was determined using a filter 
trap assay. The values for tau filament formation were normalized to the amount of 
aggregation in the absence of compound (dashed line). Negative values indicate that there 
was less detectable tau on the filter after treatment with a compound than was observed with 
monomeric tau in the absence of arachidonic acid. The amount of tau on the filter was 
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detected using A) a mixture of antibodies tau 5, tau 7 and tau 12, B) antibody TOC1, and C) 
antibody TNT1. The observation that the values are lower in B) and C) suggests that the tau 
aggregates that are retained on the filters are not in the toxic oligomeric form recognized by 
the TOC1 antibody and the phosphatase domain recognized by TNT1 antibody is not 
exposed. Values are the average of three trials ± SD. *P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001
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Figure 3. Electron microscopy of tau filament formation in the presence of azaphilone derivatives
Tau polymerization reactions were performed with 2 µM tau and 75 µM arachidonic acid 
either with or without 200 µM compound. Aliquots of the reactions were prepared for 
negative stain electron microscopy. Representative images are shown for A) no compound 
control, B) aza-7, C) aza-8, D) aza-9, E) aza-10, F) aza-11, G) aza-12, H) aza-13, I) aza-14, 
J) aza-15, K) aza-16, and L) aza-17. The scale bar in the lower right panel represents 1 µm 
and is applicable to all images.
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Figure 4. Filter trap assay of tau filament disassembly
Tau polymerization reactions were performed with 2 µM tau and 75 µM arachidonic acid at 
room temperature. After 6 hours, 200 µM compound or an equal volume of DMSO was 
added to the reactions. The compounds used are listed on the X-axis. The resulting amount 
of tau filament formation was determined using a filter trap assay. The values for tau 
filament formation were normalized to the amount of aggregates detected in the absence of 
compound (dashed line). Negative values indicate that there was less detectable tau on the 
filter after treatment with a compound than was observed with monomeric tau in the absence 
of arachidonic acid. The amount of tau on the filter was detected using a mixture of 
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antibodies tau 5, tau 7 and tau 12. Values are the average of three trials ± SD. *P ≤ 0.05; ** 
P ≤ 0.01; *** P ≤ 0.001
Paranjape et al. Page 18













Figure 5. Electron microscopy of tau filament disassembly in the presence of azaphilone 
derivatives
Tau polymerization reactions were performed with 2 µM tau and 75 µM arachidonic acid at 
room temperature. After 6 hours, 200 µM compound or equal volume of DMSO was added 
to the reactions. Aliquots of the reactions were prepared for negative stain electron 
microscopy. Representative images are shown for A) no compound control, B) aza-7, C) 
aza-8, D) aza-9, E) aza-10, F) aza-11, G) aza-12, H) aza-13, I) aza-14, J) aza-15, K) aza-16, 
and L) aza-17. The scale bar in the lower right panel represents 1 µm and is applicable for all 
images.
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Figure 6. Filament length distributions
Tau disassembly reactions were performed and viewed by electron microscopy. The 
filaments remaining following incubation with or without compound were measured, and 
placed into bins according to their length (30–50 nm, 50–100 nm, 100–150 nm, 150–200 nm 
and > 200 nm). The lengths within a bin were summed to determine the total amount of 
filament length in each bin. A) Represents the length distributions for filaments in the 
control reaction without compound. The length distributions are also shown for filaments 
remaining following incubation in the presence of B) aza-7, C) aza-8, D) aza-9, E) aza-10, 
F) aza-11, G) aza-12, H) aza-13, I) aza-14, J) aza-15, K) aza-16, and L) aza-17. Each point 
is the average distribution for images of 5 different fields ± SD.*P ≤ 0.05; ** P ≤ 0.01; *** P 
≤ 0.001.
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Figure 7. IC50 determination tau filament disassembly
Polymerization reactions at 2 µM tau and 75 µM arachidonic acid were performed at room 
temperature. After 6 hours, compounds were added to these reactions at several different 
concentrations and incubated an additional 12 hours. The resulting amount of tau filaments 
in the reaction were determined by a filter trap assay detected by a mixture of antibodies to 
normal tau (Tau 5, Tau 7 and Tau 12). The amount of polymerization was normalized to 
controls in the absence of compound (100%). The normalized data was plotted against the 
log of the inhibition concentration and fit to a dose-response curve to determine the IC50 for 
A) Aza-8, B) Aza-9, C) Aza-12 and D) Aza-13. Data points are the average of three trials ± 
SD.
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Figure 8. Filter trap assay for filament assembly and disassembly of heparin-induced tau 
filaments
A) For assembly inhibition, 100 µM aza 9 was incubated with 2 µM tau for 20 minutes 
before the addition 0.6 µM heparin. 16 hours after induction, the degree of aggregation was 
determined using the filter trap assay detected by a mixture of antibodies to normal tau (Tau 
5, Tau 7 and Tau 12), an antibody to oligomeric tau (TOC1) and an antibody to a toxic 
conformation of tau (TNT1). The average of three independent trials ± SD is shown for no 
compound controls (white bars) and 100 µM aza 9 (black bars). B) 2 µM tau and 0.6 µM 
heparin were incubated together for 21 hours prior to the addition of 100 µM aza 9 or an 
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equal volume of DMSO. Disassembly reactions proceeded for an additional 12 hours and the 
degree of aggregation was determined using the filter trap assay detected by a mixture of 
antibodies (Tau 5, Tau 7 and Tau 12), TOC1 and TNT1. The average of three independent 
trials ± SD is shown for no compound controls (white bars) and 100 µM aza 9 (black bars). 
*P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001.
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Figure 9. Microtubule assembly in the presence of the most potent azaphilone tau aggregation 
inhibitors
Tubulin was incubated with either tau protein alone or tau in the presence of A) aza-8, B) 
aza-9, C) aza-12, or D) aza-13 at a concentration of 90 µM. Microtubule assembly was 
monitored by absorbance at 340 nm (y- axis) over time (x-axis). Each point is the average of 
three independent trails ± SD. All data were fit to Gompertz growth curve (dashed and solid 
lines for no compound and 90 µM azaphilones respectively). For clarity, only every second 
time point is shown on the graph.*P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001.
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